The average participant getting a 12-mg weekly injection lost 71 pounds in 68 weeks.  "This is beyond what we see with any ...
Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the ...
Eli Lilly's retatrutide compound mimics three hormones associated with hunger regulation. "Lilly Reports Positive Results in Next-Gen Obesity Drug Trial -- Update," at 8:27 a.m. ET on Dec. 11, ...
Eli Lilly and Company has delivered significant positive developments this week, though its shares experienced a minor pullback in Wednesday's trading sessio ...
The hiring platform is rolling out smarter premium features that aim to help companies find the right candidates faster ...
Lilly’s drug works similarly to semaglutide, which is sold by Novo Nordisk under the brand names Ozempic and Wegovy. It ...